Protrieve PROTECTOR Study

S
Sabah D. Butty, MD

Primary Investigator

Enrolling By Invitation
18 years - 100 years
All
Phase N/A
1 participants needed
1 Location

Brief description of study

What is the purpose of this study?
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
 
THIS STUDY IS ENROLLING BY INVITATION ONLY

Detailed description of study

What will happen during the study?

  • The study is a prospective, single-arm, multicenter Pivotal IDE study to evaluate the safety and effectiveness of the Protrieve Sheath in patients eligible for endovascular treatment of DVT.
  • The enrollment period is expected to last approximately 18 months.
  • Each study subject will actively participate for up to 24 hours (± 12 hours) or hospital discharge, whichever is sooner, following treatment.
  • Study participation includes screening, baseline, index treatment, and the 24-hour visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Deep Venous Thrombosis, DVT, Venous Thromboembolism
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
    1. Bilateral iliofemoral DVT
    2. Clot extending into or located in the IVC
    3. In-stent thrombosis
    4. Presence of thrombosed IVC filter
    5. Other features that the investigator deems put the subject at elevated risk for thromboembolism
  3. Willing and able to provide informed consent

Exclusion Criteria:

  1. Current symptomatic PE
  2. Known anatomic inability to place Protrieve device via jugular vein access site
  3. Presence of clot extending to the IVC-Right Atrial junction or in the SVC
  4. Subject is pregnant
  5. Severe allergy to iodinated contrast agents that cannot be mitigated
  6. INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
  7. Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
  8. Subject is participating in another study that may interfere with this study
  9. Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
  10. Subject has previously completed or withdrawn from this study
  11. Limb-threatening circulatory compromise (e.g., phlegmasia)
  12. Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
  13. Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
  14. Inability to provide therapeutic anticoagulation per Investigator discretion
  15. Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
  16. Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement

Updated on 22 Apr 2025. Study ID: RADY-INARI-PROTECTOR, 24654
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center